Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RotaTeq

- PMLiVE

GSK’s Philip Thomson named Communiquetor of the Year

Recognised for stewardship of pharma company's global communications team

- PMLiVE

Setback for Merck & Co as FDA knocks back insomnia drug

US regulator asks for company to file for approval of a lower starting dose of suvorexant

- PMLiVE

GSK’s personalised cancer drug Tafinlar set for European approval

Regulatory advisors recommend the melanoma drug be licensed

- PMLiVE

GSK’s muscular dystrophy drug ‘a breakthrough’ says FDA

The antisense oligonucleotide is being developed by GlaxoSmithKline and Prosensa

- PMLiVE

Merck wins injunction against Januvia generics in India

Court blocks Aprica from launching copycat diabetes drug

National Institute for Health and Care Excellence NICE logo

NICE U-turn on GSK’s Revolade

Watchdog says yes to blood disorder drug three years after initial knockback

- PMLiVE

FDA approves Sanofi’s four-in-one flu vaccine

But wants more safety data for hepatitis B vaccine from Dynavax

- PMLiVE

GSK fires senior Chinese scientist over data fabrication

Pharma company dismisses head of Chinese R&D unit after tip-off about inaccurate MS data in journal

- PMLiVE

GSK buys rights to MorphoSys’ arthritis antibody

Pharma company will pay up €445m to develop and commercialise MOR103

- PMLiVE

FDA to review restrictions on GSK’s diabetes drug Avandia

Advisory committee to discuss re-analysis of diabetes drug’s safety data

- PMLiVE

GSK’s Tyverb/ Tykerb disappoints in gastric cancer trial

Fails to improve overall survival in proposed new indication

- PMLiVE

ASCO: Merck and BMS trumpet melanoma trials

Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links